Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study

Human Vaccines

Volumn 5, Issue 3, 2009, Pages 141-150

  Fairman, Jeff ^a   Moore, Joseph ^b   Lemieux, Mathieu ^b   Van Rompay, Koen ^b   Geng, Yongzhi ^b   Warner, John ^a   Abel, Kristina ^b,c  

^a Juvaris BioTherapeutics Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjuvant; HIV; Vaccine

Indexed keywords

ALPHA INTERFERON; CATIONIC LIPOSOME DNA COMPLEX; DRUG CARRIER; INACTIVATED VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 1BETA; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE ACTIVATION; CD4 CD8 RATIO; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG POTENTIATION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PILOT STUDY; RHESUS MONKEY; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; B-LYMPHOCYTES; IMMUNOLOGIC MEMORY; LIPOSOMES; MACACA MULATTA; MALE; OLIGODEOXYRIBONUCLEOTIDES; PILOT PROJECTS; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T-LYMPHOCYTES;

EID: 67549149326     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.3.6589     Document Type: Article

References (57)

1. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008; 14:617-21.
2. Desrosiers RC. Prospects for an AIDS vaccine. Nat Med 2004; 10:221-3.
3. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233-6.
4. + T cells in control of SIV replication. J Clin Invest 2004; 113:836-45.
5. Garber DA, Silvestri G, Feinberg MB. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis 2004; 4:397-413.
6. Garber DA, Feinberg MB. AIDS vaccine development: the long and winding road. AIDS Rev 2003; 5:131-9.
7. Doherty PC, Turner SJ. The challenge of viral immunity. Immunity 2007; 27:363-5.
8. Letvin NL. Correlates of immune protection and the development of a human immunodeficiency virus vaccine. Immunity 2007; 27:366-9.
9. Janeway CA Jr, Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin Immunol 1998; 10:349-50.
10. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20:197-216.
11. Pulendran B. Variegation of the immune response with dendritic cells and pathogen recognition receptors. J Immunol 2005; 174:2457-65.
12. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85:85-95.
13. Hemmi H, Akira S. TLR signalling and the function of dendritic cells. Chem Immunol Allergy 2005; 86:120-35.
14. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006; 124:849-63.
15. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-95.
16. + effector and memory T cell generation. Nat Immunol 2003; 4:835-42.
17. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
18. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002; 109:1519-26.
19. Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997; 9:4-9.
20. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296:298-300.
21. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997; 186:1623-31.
22. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon gamma. Proc Natl Acad Sci USA 1996; 93:2879-83.
23. Krieg AM. CpG DNA: a novel immunomodulator. Trends Microbiol 1999; 7:64-5.
24. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374:546-9.
25. Tokunaga T, Yamamoto T, Yamamoto S. How BCG led to the discovery of immunostimulatory DNA. Jpn J Infect Dis 1999; 52:1-11.
26. Altin JG, Parish CR. Liposomal vaccines - targeting the delivery of antigen. Methods 2006; 40:39-52.
27. Altin JG, van Broekhoven CL, Parish CR. Targeting dendritic cells with antigen-containing liposomes: antitumour immunity. Expert Opin Biol Ther 2004; 4:1735-47.
28. Zhu N, Liggitt D, Liu Y, Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science 1993; 261:209-11.
29. Gowen BB, Fairman J, Smee DF, Wong MH, Jung KH, Pace AM, et al. Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res 2006; 69:165-72.
30. Fitzgerald-Bocarsly P. Natural interferon-alpha producing cells: the plasmacytoid dendritic cells. Biotechniques 2002; 2:4-9.
31. Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev 2008; 19:3-19.
32. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434:772-7.
33. Ito T, Wang YH, Liu YJ. Plasmacytoid dendritic cell precursors/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9. Springer Semin Immunopathol 2005; 26:221-9.
34. Lifson JD, Rossio JL, Piatak M Jr, Bess J Jr, Chertova E, Schneider DK, et al. Evaluation of the safety, immunogenicity and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retroviruses 2004; 20:772-87.
35. Frank I, Piatak M Jr, Stoessel H, Romani N, Bonnyay D, Lifson JD, et al. Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCs. J Virol 2002; 76:2936-51.
36. + T-cell responses. J Acquir Immune Defic Syndr 2003; 34:7-19.
37. Teleshova N, Kenney J, Jones J, Marshall J, Van Nest G, Dufour J, et al. CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFNgamma-secreting simian immunodeficiency virus-specific T cells. J Immunol 2004; 173:1647-57.
38. Abel K, Pahar B, Van Rompay KK, Fritts L, Sin C, Schmidt K, et al. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. J Virol 2006; 80:6357-67.
39. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78.
40. + T cells by infant but not adult macaque regulatory T cells: implications for SIV disease progression. J Exp Med 2007; 204:2679-92.
41. O'Garra A, Hosken N, Macatonia S, Wenner CA, Murphy K. The role of macrophage- and dendritic cell-derived IL12 in Th1 phenotype development. Res Immunol 1995; 146:466-72.
42. Trinchieri G, Gerosa F. Immunoregulation by interleukin-12. J Leukoc Biol 1996; 59:505-11.
43. Wille-Reece U, Flynn BJ, Lore K, Koup RA, Miles AP, Saul A, et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 2006; 203:1249-58.
44. Kubota M, Miller CJ, Imaoka K, Kawabata S, Fujihashi K, McGhee JR, et al. Oral immunization with simian immunodeficiency virus p55gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates. J Immunol 1997; 158:5321-9.
45. + T cells. Nature 2005; 434:1148-52.
46. + T cells in multiple tissues during acute SIV infection. Nature 2005; 434:1093-7.
47. Mattapallil JJ, Letvin NL, Roederer M. T-cell dynamics during acute SIV infection. AIDS 2004; 18:13-23.
48. Gourley TS, Wherry EJ, Masopust D, Ahmed R. Generation and maintenance of immunological memory. Semin Immunol 2004; 16:323-33.
49. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002; 2:251-62.
50. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004; 78:5535-45.
51. Foulds KE, Wu CY, Seder RA. Th1 memory: implications for vaccine development. Immunol Rev 2006; 211:58-66.
52. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188:2199-204.
53. + T cell responses. J Immunol 2000; 165:6133-41.
54. Mondelli MU, Cerino A, Segagni L, Meola A, Cividini A, Silini E, et al. Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? Antiviral Res 2001; 52:153-9.
55. Ostrowski M, Galeota JA, Jar AM, Platt KB, Osorio FA, Lopez OJ. Identification of neutralizing and nonneutralizing epitopes in the porcine reproductive and respiratory syndrome virus GP5 ectodomain. J Virol 2002; 76:4241-50.
56. Lu Y, Brosio P, Lafaile M, Li J, Collman RG, Sodroski J, et al. Vaginal transmission of chimeric simian/human immunodeficiency viruses in rhesus macaques. J Virol 1996; 70:3045-50.
57. Miller CJ, McChesney MB, Lu X, Dailey PJ, Chutkowski C, Lu D, et al. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J Virol 1997; 71:1911-21.